Subscribe To
: AstraZeneca shares slump after Phase 3 lung cancer drug study
AstraZeneca’s AZNUK:AZN shares slumped 6% in premarket trade. The U.K. drugmaker said its datopotamab deruxtecan treatment showed positive results in patients with advanced non-small cell lung cancer in a clinical Phase 3 trial. AstraZeneca said the trial will continue to asses the dual primary endpoint of overall survival. Analysts at UBS pointed out the company did […] The post : AstraZeneca shares slump after Phase 3 lung cancer drug study appeared first on ForexTV...
Read More
Posted: Jul 3 2023, 09:36
Author Name: forextv
Views: 081098